Clinical Vignette Series : 34th Annual Chemotherapy Foundation Symposium : Innovative Cancer Therapy for Tomorrow
WebcastFaculty
OVERVIEW
Clinical Vignette Series : 34th Annual Chemotherapy Foundation Symposium : Innovative Cancer Therapy for Tomorrow is organized by Physicians Education Resource, LLC (PER) and will be held during Feb 28, 2017 - Feb 28, 2018.
The target audience for this medical event is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to participate. This CME Conference has been approved for a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Objectives :
At the conclusion of this activity, participants should be better prepared to :
• Report practice-changing results from clinical trials that impact evolving treatment paradigms in hematologic and solid tumor management.
• Outline testing methods for prognostic and predictive markers that inform personalized care strategies in the treatment of cancer.
• Discuss optimized chemotherapeutic, targeted, and immunotherapy strategies based on clinical trial evidence.
• Describe methods to monitor efficacy and manage treatment-related adverse events in multiple lines of cancer management.
• Place recent clinical trial findings in the context of evolving treatment pathways to improve care for patients with cancer.
Additional details will be posted as soon as they are available.
The target audience for this medical event is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to participate. This CME Conference has been approved for a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Objectives :
At the conclusion of this activity, participants should be better prepared to :
• Report practice-changing results from clinical trials that impact evolving treatment paradigms in hematologic and solid tumor management.
• Outline testing methods for prognostic and predictive markers that inform personalized care strategies in the treatment of cancer.
• Discuss optimized chemotherapeutic, targeted, and immunotherapy strategies based on clinical trial evidence.
• Describe methods to monitor efficacy and manage treatment-related adverse events in multiple lines of cancer management.
• Place recent clinical trial findings in the context of evolving treatment pathways to improve care for patients with cancer.
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links